Randox Laboratories will showcase its new automated test for group II secretory phospholipase A2 (sPLA2-IIA) as a biomarker of cardiovascular risk for research applications at the American Association for Clinical Chemistry (AACC) meeting, to be held August 4-8 in Anaheim, CA.
Elevated levels of sPLA2-IIA signify less capacity of high-density lipoprotein (HDL) cholesterol to remove cholesterol-rich cells, which increases the risk for primary and secondary cardiovascular events. The biomarker may be checked along with other routinely tested markers, including HDL, low-density lipoprotein cholesterol, and triglycerides.
The assay can be used with a wide range of clinical chemistry analyzers, Randox said in a statement.
